Report of the 6th International Workshop on PET in lymphoma, Leuk. Lymphoma, vol.58, pp.2298-303, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01742975
Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group, J Clin Oncol, vol.32, pp.3048-58, 2014. ,
Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification, J Clin Oncol, vol.32, pp.3059-67, 2014. ,
Mantle cell lymphoma: 2012 update on diagnosis, riskstratification, and clinical management, Am J Hematol, vol.87, pp.604-613, 2012. ,
The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, pp.2375-90, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01800015
Guideline for the management of mantle cell lymphoma, Br J Haematol, vol.182, pp.46-62, 2018. ,
A british society for haematology good practice paper on the diagnosis and investigation of patients with mantle cell lymphoma, Br J Haematol, vol.182, pp.46-62, 2018. ,
Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, pp.62-71, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01613400
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma, Blood, vol.111, pp.558-65, 2008. ,
Utility of FDG-PET scanning in lymphoma by WHO classification, Blood, vol.101, pp.3875-3881, 2003. ,
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group, Eur J Nucl Med Mol Imaging, vol.37, pp.1633-1675, 2010. ,
What is the role of 18 F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?, Leukemia Lymphoma, vol.49, pp.1653-1659, 2008. ,
Fluorodeoxyglucose-Positron-emission tomography findings in mantle cell lymphoma, Clin Lymphoma Myeloma Leukemia, vol.11, pp.261-267, 2011. ,
Utility of positron emission tomography scans in mantle cell lymphoma, Am J Hematol, vol.86, pp.841-846, 2011. ,
Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD, Cancer, vol.118, pp.3565-70, 2012. ,
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma, J Clin Oncol, vol.23, pp.4643-51, 2005. ,
Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics, Nat Rev Cancer, vol.7, pp.750-62, 2007. ,
FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome, Nucl Med Commun, vol.30, pp.770-778, 2009. ,
Predictive power of FDG-PET parameters at diagnosis and after induction in patients with mantle cell lymphoma, interim results from the LyMa-PET project, conducted on behalf of the lysa group, Blood, vol.126, p.335, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01300802
Positron emission tomography in mantle cell lymphoma, Leukemia Lymphoma, vol.49, pp.1693-701, 2008. ,
Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?, Leuk. Lymphoma, vol.55, pp.2484-2493, 2014. ,
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma, Blood, vol.123, pp.2953-2962, 2014. ,
Hematopoietic cell transplantation for mantle cell lymphoma: predictive value of pretransplant positron emission tomography/computed tomography and bone marrow evaluations for outcomes, Clin Lymphoma Myeloma Leuk, vol.14, pp.114-135, 2014. ,
Impact of pretransplantation (18)F-fluorodeoxy glucose-positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-hodgkin lymphoma, Biol Blood Marrow Transplant, vol.21, pp.1605-1616, 2015. ,
PET-CT confirmed complete remission and MRD negativity in mantle cell lymphoma patients treated with R-hyper-CVAD results in excellent outcome in the absence of autologous stem cell transplantation: a single-centre case for a transplant-free approach, Intern Med J, vol.46, pp.1113-1117, 2016. ,
Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma, Hematol Oncol, vol.36, pp.110-115, 2018. ,
Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance, Hematol Oncol, vol.36, pp.773-781, 2018. ,
18F-FDG PET for measurement of response and prediction of outcome to relapsed or refractory mantle cell lymphoma therapy with bendamustine-rituximab, J Nucl Med, vol.58, pp.62-70, 2017. ,